Cargando…
Is it time to switch to bivalirudin for ECMO anticoagulation?
For decades, unfractionated heparin (hereafter, heparin) has been the primary anticoagulant used for extracorporeal membrane oxygenation (ECMO) support. More recently, however, bivalirudin, a direct thrombin inhibitor, has emerged as an alternative. This systematic review based on PRISMA guidelines,...
Autores principales: | Navaei, Amir, Kostousov, Vadim, Teruya, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476497/ https://www.ncbi.nlm.nih.gov/pubmed/37671395 http://dx.doi.org/10.3389/fmed.2023.1237601 |
Ejemplares similares
-
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
por: Trigonis, Russell, et al.
Publicado: (2022) -
Novel Coagulation Test Detects Anticoagulation Resistance and Is Associated With Thrombotic Events in Pediatric Patients Requiring Extracorporeal Membrane Oxygenation
por: Frydman, Galit H., et al.
Publicado: (2022) -
Bivalirudin and post-cardiotomy ECMO: a word of caution
por: Ranucci, Marco
Publicado: (2012) -
Editorial: Hemostasis in ECMO and VAD
por: Teruya, Jun, et al.
Publicado: (2019) -
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
por: Valdes, Carlos A., et al.
Publicado: (2023)